Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Spruce Biosciences, Inc. NASDAQ:SPRB | $116.37M | $40.49 | Not rated | -1.9 | -63.21% |
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $106.93M | $2.45 | Not rated | -5.3 | +31.46% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $87.79M | $0.36 | Not rated | -2.1 | -79.19% |
OS Therapies Incorporated AMEX:OSTX | $34.86M | $0.74 | Not rated | -2.0 | -30.30% |
INmune Bio, Inc. NASDAQ:INMB | $29.72M | $0.96 | Not rated | -1.1 | +25.17% |
Adicet Bio, Inc. NASDAQ:ACET | $26.03M | $2.78 | Overvalued | -0.8 | -40.15% |
Cue Biopharma, Inc. NASDAQ:CUE | $20.56M | $2.83 | Not rated | -6.7 | -19.01% |
Continue the stock analysis
Jump to another research area for this company.